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Protein deposition as amyloid ﬁbrils underlies more than twenty severely debilitating human
disorders. Interestingly, recent studies suggest that all peptides and proteins possess an
intrinsic ability to assemble into amyloid ﬁbrils similar to those observed in disease states. The
common properties and characteristics of amyloid aggregates thus oﬀer the prospect that
simple model systems can be used to systematically assess the factors that predispose a native
protein to form amyloid ﬁbrils and understand the origin and progression of fatal disorders
associated with amyloid formation. Here, we report the de novo design of a 17-residue peptide
model system, referred to as ccb, which forms a protein-like coiled-coil structure under
ambient solution conditions but can be easily converted into amyloid ﬁbrils by raising the
temperature. Oxidation of methionine residues at selected hydrophobic positions completely
abolished amyloid ﬁbril formation of the peptide while not interfering with its coiled-coil
structure. This ﬁnding indicates that a small number of site-speciﬁc hydrophobic interactions
can play a major role in the packing of polypeptide chain segments within amyloid ﬁbrils. The
simplicity and characteristics of the ccb system make it highly suitable for probing molecular
details of the assembly of amyloid structures.
KEY WORDS: Coiled coil; de novo design; amyloid.
INTRODUCTION
The deposition of proteins in the form of amyloid
ﬁbrils and plaques is the characteristic feature of more
than twenty degenerative conditions affecting either
the central nervous system or a variety of peripheral
tissues (Lansbury 1999; Perutz 1999; Prusiner 2001;
Sacchettini and Kelly 2002; Taylor et al. 2002; Aguzzi
and Haass 2003; Stefani and Dobson 2003). These
conditions include Alzheimer’s, Parkinson’s and the
prion diseases, several forms of fatal systemic amy-
loidosis, and at least one condition associated with
medical intervention (haemodialysis). Due to the
severity of these diseases, they have an enormous
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impact to our present-day human health and welfare.
The detailed structural characterization of amyloid
ﬁbrils and the systematic assessment of factors that
predispose a native protein to misfold into amyloid
aggregates are therefore indispensable for under-
standing the origin and progression of the diseases.
Consistent with the propensity of seemingly unrelated
proteins to polymerize in vivo, recent studies suggest
that many peptides and proteins not associated with
amyloid diseases possess an intrinsic ability to
assemble into amyloid ﬁbrils similar to those observed
in disease states under appropriate conditions (Chiti
et al. 1999; Fandrich et al. 2001). Furthermore, it has
been suggested that amyloid ﬁbril formation is an
evolutionary conserved biological pathway used to
generate natural product nanostructures (Kelly and
Balch 2003). As a result, amyloid ﬁbrils have attracted
much attention for nanotechnological and material
science applications (Zhang 2003).
Interestingly, all amyloid ﬁbrils share common
characteristics. A key feature of all amyloid ﬁbrils is
their apparently similar molecular architecture. Elec-
tron micrographs of amyloid deposits from sequen-
tially or structurally unrelated peptides and proteins
frequently show the presence of uniform and un-
branched ﬁbrils with a diameter of 7 to 12 nm. These
ﬁbrils are often several micrometers in length and are
usually composed of many protoﬁlaments (Serpell et
al. 1997). The internal structure of amyloid ﬁbrils is
deﬁned by their characteristic X-ray ﬁbre diﬀraction
patterns that are generally interpreted as a ‘‘cross-b’’
structure. In this type of structure, the polypeptide
chain is organized in laminated layers of b-sheets ar-
ranged parallel to the ﬁbre axis with their constituent
b-strands running approximately perpendicular to the
long ﬁbril axis (Sunde et al. 1997). Together with the
requirement of a nucleation-dependent step for pro-
ductive assembly (Rochet and Lansbury 2000), these
ﬁndings strongly suggest that amyloid ﬁbrils are
formed by a common self-assembly pathway.
Although in recent years substantial progress has
been made in our understanding of the overall char-
acteristics of amyloid structures and their formation,
detailed knowledge of the intra- and inter-molecular
interactions that promote and stabilize these highly
organized assemblies is still lacking. Furthermore, the
molecular details underlying the process of amyloid
formation are still poorly understood. These gaps in
our knowledge result from the non-crystalline nature
of amyloid ﬁbrils, which makes their high-resolution
structural analysis extremely challenging, and from
the complexity and diversity of the different proteins
that form amyloid aggregates. It is generally
acknowledged that one major factor for driving ﬁbril
formation is the generic property of the polypeptide
backbone to form hydrogen bonds. A number of
studies indicate, however, that the amino acid
sequence can profoundly inﬂuence the propensity of a
polypeptide chain to form amyloid ﬁbrils. In such
cases, the effects of limited sequence changes can be
rationalized in terms of perturbations in the various
native or nonnative protein conformations (Booth et
al. 1997; Ramirez-Alvarado et al. 2000, Villegas et al.
2000). In the case of globular proteins, at least partial
unfolding is an essential step in the conversion to
amyloid ﬁbrils. Thus, destabilization of the native
state of natural proteins has been reported to be
directly coupled to the propensity to form amyloid
deposits and is generally accepted as a major factor
controlling amyloid formation (Hurle et al. 1994;
McCutchen et al. 1995; Booth et al. 1997; Chiti et al.
2000; Ramirez-Alvarado et al. 2000; Zhu et al. 2003).
It is well established, however, that changes in the
hydrophobicity, charge, secondary structure propen-
sity, and residual a-helical structure in the unfolded
state, occurring as a result of mutations, can inﬂuence
the probability of amyloid ﬁbril formation (Nielsen
et al. 2001; Chiti et al. 2002; Hammarstrom et al.
2002; Lopez De La et al. 2002; Tjernberg et al. 2002a;
Burke et al. 2003; Chiti et al. 2003; Smith et al. 2003).
In some cases, it appears that mutations within dis-
tinct polypeptide chain segments can promote ﬁbril
formation (Nielsen et al. 2001, Ciani et al. 2002)
suggesting that speciﬁc regions are of particular
importance in the nucleation or stabilization of the
amyloid structure. Juxtaposition of hydrophobic
and/or polar/charged sequence segments may play a
particularly important role in the organization of the
b-sheets within the protoﬁlament (Perutz et al. 1994;
Zhang and Rich 1997; West et al. 1999; Tjernberg
et al. 1999; Takahashi et al. 2000; Balbirnie et al.
2001). Together, these ﬁndings suggest that both
long- and short-range interactions within a distinct
sequence context can participate in the process of
amyloid formation.
The common properties and characteristics of
amyloid aggregates offer the prospect that simple
model systems can be used to systematically assess
the factors that predispose a native protein to form
amyloid ﬁbrils and understand the origin and pro-
gression of fatal disorders associated with amyloid
formation. We report here a simpliﬁed peptide sys-
tem, referred to as ccb, successfully designed de novo
to fold into a a-helical coiled-coil conformation
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under ambient conditions, but to transform into
amyloid ﬁbrils at elevated temperatures. We demon-
strate that its simplicity and characteristics make the
ccb system highly suitable for probing molecular de-
tails of the assembly of amyloid structures.
MATERIALS AND METHODS
Peptide Synthesis and Derivatization
Chain assembly was carried out on a Milligen 9050 auto-
mated peptide synthesizer (continuous ﬂow), starting with an
Fmoc-PAL-PEG-MBHA resin for establishing the C-terminal
carboxamide (Albericio et al. 1990), and using chemical protocols
based on Fmoc chemistry. The required Fmoc amino acids (3
equiv.) were incorporated using their 2,4,5-trichlorophenyl esters
with minimum reaction times of 30 min. Side chains were pro-
tected with the following groups: tert-butyl for serine and
glutamic acid; 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl for
arginine. We recommend double coupling for the incorporation
of arginine-3,8,10 and 15, isoleucine-2 and 9, leucine-5, and
serine-1. These Fmoc-amino acids (3 equiv.) were incorporated
using TPTU (3 equiv.) as coupling agent in the presence of di-
isopropylamine (6 equiv.). The completed peptide resins were
simultaneously deprotected and cleaved by treatment with
TFA:H2O (95:5, v/v; for ccb-p) or TFA:H2O:EDT (76:4:20, v/v/
v; for ccb-Met) for 3 h at room temperature. The ﬁltrate from
each cleavage reaction was precipitated in diisopropyl ether-
petroleum ether (1:1, v/v; at 0C), and the precipitate was col-
lected by ﬁltration. The crude peptides were puriﬁed by medium-
pressure liquid chromatography using a Merck C18-column
eluted with an acetonitrile-water gradient containing 0.1% TFA.
Controlled oxidation of methionines in ccb-Met was performed
as follows (Garcı´a-Echeverrı´a 1996): 70 mg of puriﬁed ccb-Met were
dissolved in 6.3 ml ofMeCN:H2O (1:1, v/v) and 0.7 ml ofH2O2-30%
were added.Theprogress of the reactionwasmonitored byanalytical
HPLC andMALDI-TOF analyses. After full conversion of ccb-Met
to the target peptide, the reaction was quenched by addition of
ascorbic acid and the crudemixturewas puriﬁedbymedium-pressure
liquid chromatography as described above. The purity of the ﬁnal
peptide was veriﬁed by reversed-phase analytical HPLC on a Chro-
molith SpeedRODRP18e column (50· 4.6 mm): linear gradient over
2.5 min of MeCN/0.09% TFA and H2O/0.1% TFA from 6:44 to
7:3 v/v; ﬂow rate 3.0 ml/min, detection at 215 nm. Single peaks were
observed at following retention times tR=2.03 min, 2.01 min, and
1.97 min for ccb-p, ccb-Met, and ccb-MetO, respectively. MALDI-
TOF mass spectrometric analyses revealed molecular masses within
0.1% of the expected values (negative-ion mode): 2092.7 (calc.
2093.5, ccb-p), 2171.7 (calc. 2171.6, ccb-Met) and 2203.6 (calc.
2203.6, ccb-MetO). Quantitative amino acid analyses (Beckman
6300 amino acid analyzer) of the puriﬁed peptides after acid hydro-
lyzes gave the expected composition.
Circular Dichroism Spectroscopy
Peptide samples were analyzed in 10 mM sodium phosphate
buffer (pH 7.4) containing 150 mM NaCl (PBS). Far-ultraviolet
(UV) circular dichroism (CD) spectra and urea unfolding proﬁles
were recorded on a Jasco J-720 spectropolarimeter (Jasco Inc.)
equipped with a temperature controlled quartz cell of 0.1 cm
pathlength. The recorded spectra were evaluated with the Jasco
software package. The midpoints of the urea-induced equilibrium
transitions, Cm’s, and thermal melts, Tm’s, were taken as the
maximum of the derivative d(Fraction transformed)/d[urea] and
d[Q]222/dT, respectively.
Analytical Ultracentrifugation
Analytical ultracentrifugation (AUC) was performed at 5C
on an Optima XL-A analytical ultracentrifuge (Beckman Instru-
ments) equipped with an An-60Ti rotor. The peptides were ana-
lyzed in PBS and peptide concentrations were adjusted to 0.1–
0.5 mg/ml. Sedimentation equilibrium experiments were performed
between 40,000 and 50,000 rpm. The partial speciﬁc volumes of the
peptides were calculated from their amino-acid sequence. Solvent
density for PBS was taken as 1.005 g/ml.
Negative Staining and Transmission Electron
Microscopy
For negative staining, sample aliquots of 5 ll were applied to a
weakly glow-discharged carbon coated 400-mesh/inch copper grid.
The sample was allowed to adsorb for 30 sec, washed twice with
water, and negatively stained for 20 sec with 2% (w/v) uranyl
acetate. Specimens were examined in a Philips Morgagni trans-
mission electron microscopy (TEM) operated at 80 kV. Micro-
graphs were recorded with a Megaview III CCD camera at a
nominal magniﬁcation of 30,000· and 50,000·.
Congo Red Staining
The method of Janek et al. (Janek et al. 1999) was used with
slight modiﬁcations. Brieﬂy, a saturated solution of Congo red
(Aldrich) was prepared in 80% ethanol. 10–20 ll of a concentrated
ﬁlamentous peptide preparation was placed on a glass slide, air
dried and incubated for 10 min with the Congo red stock solution.
After being washed with water and ethanol, the stained samples
were examined under the microscope with bright and polarized
light.
RESULTS AND DISCUSSION
Design Rationale
De novo protein design provides a powerful tool
to elucidate and validate fundamental principles of
protein structure and folding (DeGrado et al. 1999).
The design of a preferably short and simple peptide
sequence that adopts a native-like fold while
displaying conformational interconversion (e.g., from
a-helix to b-sheet) and ﬁbril formation should be
beneﬁcial for exploring the mechanistic details of
amyloid formation. For the purpose of this study, we
selected the a-helical coiled-coil as a platform for the
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design. The a-helical coiled-coil is the most wide-
spread subunit oligomerization motif found in pro-
teins (Lupas 1996; Kammerer 1997; Burkhard et al.
2001). This abundance reﬂects the importance and
involvement of the motif in a large number of bio-
logical processes. Coiled coils consist of two to ﬁve
amphipathic right-handed a-helices that ‘‘coil’’
around each other in a slight supertwist. The se-
quences of left-handed coiled-coils are characterized
by a heptad repeat of seven residues denoted a to g
with a 3,4-hydrophobic repeat of mostly apolar
amino acids at positions a and d. Interactions be-
tween the core residues a and d and its two ﬂanking
positions e and g determine the number of strands,
the parallel or antiparallel orientation of a-helices,
and the homo- or heterotypic association of subunits
into a coiled-coil (Cohen and Parry 1990; Lupas
1996; Kohn and Hodges 1998).
Because of its simplicity, the coiled-coil struc-
tural motif has been extensively studied and used as
a model system for de novo protein design (Kohn
and Hodges 1998; DeGrado et al. 1999). Accord-
ingly, the sequence-to-structure relationship of
coiled-coils is well established. It has been shown
that peptides comprising 15 to 21 residues can form
stable coiled-coil structures (Su et al. 1994; Burk-
hard et al. 2000), whereas the sequence length of a
b-strand in an amyloid ﬁbril is in the range of 5 to
26 residues (Benzinger et al. 1998; Tenidis et al.
2000). Based on the concept of coiled-coil trigger
sequences (Kammerer et al. 1998; Steinmetz et al.
1998; Frank et al. 2000; Kammerer et al. 2001) and
in combination with available information on pep-
tides that undergo structural transitions (Zhang and
Rich 1997; West et al. 1999; Takahashi et al. 2000;
Ciani et al. 2002), we designed de novo a synthetic
17-residue peptide system, referred to as ccb, with
the potential to fold into both a stable a-helical
coiled-coil and a b-sheet type of structure (Fig. 1).
To keep the design as simple as possible, the
number of different amino acids in the peptide was
limited to a minimum of seven. Amino acids with
high propensities for both the a-helix and b-strand
structure were chosen (Minor and Kim 1994; Cha-
krabartty and Baldwin 1995). To guarantee forma-
tion of a stable and speciﬁc two-stranded parallel
coiled-coil structure, hydrophobic Ile and Leu resi-
dues were placed at the a and d positions of the two
heptad repeats, respectively (Harbury et al. 1993).
Positions b, c, e, and g were occupied with Arg and
Glu residues in a manner to allow for i to i+3 and i
to i+4 intrahelical and i to i¢+5 (i.e., between the
heptad e and g0 positions that ﬂank the hydrophobic
a and d core positions; Fig. 1b) interhelical attractive
electrostatic interactions throughout the sequence
(Fig. 1b, dashed curved lines). Such attractive elec-
trostatic interactions are known to stabilize and
direct parallel in-register chain orientation of coiled-
coil structures (Kohn and Hodges 1998). No putative
repulsive electrostatic interactions were allowed in the
design. The core sequence was ﬂanked by N- and C-
terminal acetylated Ser and amidated Gly capping
residues (Richardson and Richardson 1998), respec-
tively, that are expected to stabilize further the coiled-
coil structure (Lu et al. 1999).
Amyloid ﬁbrils are cross-b structures organized in
laminated layers of b-sheets that are arranged parallel
to the ﬁbre axis (Sunde et al. 1997). Thus, for
sequences to self-assemble into amyloid aggregates
they must contain the information to form multi-
meric b-sheets. Binary sequence patterning of
hydrophobic and polar residues was found to
strongly favor b-sheet and amyloid formation of de-
signed peptides (Zhang and Rich 1997; West et al.
1999). This alternating pattern matches the structural
repeat of b-strands with successive side chains
pointing up and down throughout the sequence
(Fig. 1c). Thus, such sequence elements are predis-
posed to form amphipathic b-strands that bury their
hydrophobic faces by aggregating into large b-sheet
and cross-b structures (Hecht et al. 2004). In order to
create two short seven and six residue long binary
hydrophobic/polar sequence patterns in the ccb
sequence platform, hydrophobic Ala and Leu resi-
dues were placed at the remaining f7 and f14 posi-
tions (Fig. 1a). As a result, the parent peptide,
referred to as ccb-p, has the potential for establishing
complementary inter-chain interactions between
hydrophobic and polar residues in both a-helical
coiled-coil (Fig. 1b) and b-sheet (Fig. 1c) assemblies.
To test the hypothesis that speciﬁc hydrophobic
packing interactions play a crucial role in driving ccb
amyloid formation, a peptide variant was prepared in
which Met residues were placed at the heptad f7 and
f14 positions, referred to as ccb-Met. Mutations of
heptad f residues are not expected to interfere with
the coiled-coil structure as these positions do not
participate in the formation of the hydrophobic core
(Fig. 1b). Methionine was chosen for three reasons.
First, methionine does not show a dramatically dif-
ferent intrinsic propensity to favor either a-helix or b-
sheet structures when compared to Ala or Leu
(Minor and Kim 1994; Chakrabartty and Baldwin
1995). Thus no major conformational eﬀect on the
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denatured state is expected. Second, the two methi-
onine residues do not substantially alter the overall
hydrophobicity of the ccb peptide variant: a diﬀer-
ence of only 0.11 in the Grand average hydrophaty
(GRAVY; (Kyte and Doolittle 1982)) index scores is
calculated between ccb-p and ccb-Met. Finally, the
methionine side chain can be chemically oxidized to a
polar sulfoxide group. The introduction of one single
oxygen atom switches the character of the residue
from hydrophobic to polar and, as a consequence of
this change, disrupts the two short binary hydro-
phobic/polar sequence patterns present in the ccb
sequence (Fig. 1c). This form of the peptide is re-
ferred to as ccb-MetO.
The use of methionine in this work expands the
‘‘switchable residue’’ concept of Dado and Gellman,
who used methionine residues to control the sec-
ondary structure propensity (i.e., a-helix versus
b-sheet) of an 18-mer peptide (Dado and Gellman
1993). The oxidation state of methionine has also
been used to control the folding preferences of leu-
cine-zipper peptides (Garcı´a-Echeverrı´a 1996).
Design Validation
The validity of the design was thoroughly chal-
lenged by various biophysical methods. The a-helical
coiled-coil state of the three peptides at 4Cwas probed
by CD spectroscopy. The far-UVCD spectra recorded
at a concentration of 0.2 mg/ml conﬁrmed substantial
a-helical structure for the peptides with well-deﬁned
minima at 208 and 222 nm (Fig. 2a). Sedimentation
equilibrium studies under similar conditions yielded
averagedmolecular masses of 5.9, 6.3, and 6.2 kDa for
ccb-p, ccb-Met, and ccb-MetO, respectively. These
values are consistent with the formation of trimeric
structures (the sequence derived molecular masses of
Fig. 1. Design of the ccb model system. (a), Amino acid sequence of ccb. The heptad repeats, the Ncap-acetyl (Ac) and Ccap-amide (NH2)
capping residues, and the sequence patterning of polar (p) and hydrophobic (h) residues are indicated. (b), Helical wheel representation of the
intended two-stranded ccb coiled-coil as seen along the coiled-coil axis from the N-terminus. The cross indicates the dimerization interface
formed by the a and d hydrophobic core residues. Dashed curved lines indicate sites of designed intra- (i, i+3 and i, i+4) and interhelical (i,
i0+5) attractive electrostatic interactions between Glu and Arg residues. (c), Schematic representation of ccb in its b-strand conformation as
seen along the b-sheet plane. The dashed boxes indicate the amphipathic b-strand stretches formed by the two binary h/p sequence patterns
(dashed lines in A). Residues are colored according to their physicochemical properties: Blue, positively charged; red, negatively charged;
green, hydrophobic; black, polar and Gly.
Design of a Coiled Coil-based Model Peptide System 47
the monomeric peptides range between 2.1 and
2.2 kDa). The stabilities of ccb-p and the two methi-
onine variants were probed at 4C by urea denatur-
ation proﬁles recorded byCDat 222 nm (Fig. 2b).At a
peptide concentration of 0.15 mg/ml, ccb-p, ccb-Met
and ccb-MetO revealed sigmoidal denaturation pro-
ﬁles characteristic of a two-state helix-coil transition
with single inﬂection points, Cm, centered at 3.4, 2.4
and 1.5 M urea, respectively.
The overall fold and topology of ccb-p in its
a-helical state was assessed by X-ray crystallography.
Crystals were obtained at 4C and the structure was
solved to a resolution of 2 A˚ using the molecular
replacementmethod (Kammerer et al. 2004).As shown
in Figure 2c, ccb-p forms a bundle of three parallel
in-register a-helices that wrap around each other in a
slightly left-handedmanner. The trimer has an average
length of 27 A˚ and an average diameter of 23 A˚.
Fig. 2. ccb forms a stable native-like coiled-coil structure at low temperatures. (a), CD spectra recorded at 4C from 0.2 mg/ml ccb-p (d), ccb-
Met (m), and ccb-MetO (j) peptide solutions. (b), Urea-induced unfolding proﬁles of 0.15 mg/ml peptide solutions monitored by CD at
222 nm and 4C. The symbols are the same as in A. All CD measurements were carried out in PBS. (c), Side and top views of the 2 A˚
resolution crystal structure of the three-stranded ccb-p coiled coil (PDB ID code 1S9Z) in stereo. The monomer backbones and the residue
side chains are represented as ribbons and sticks, respectively.
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Consistentwith awell-deﬁned coiled-coil structure, the
hydrophobic Ile and Leu side-chains occupying the a
and d core positions are packed in a ‘knobs-into-holes’
fashion (Lupas, 1996). Arg8 and Glu13¢ form a tight
belt of g to e¢ interhelical salt bridges. Contrary to the
intendeddesign, none of theGlu andArg residues form
intrahelical salt-bridges but are mostly engaged in
establishing crystal-packing contacts. The acetyl moi-
ety of all three Ser1 residues was found to cap the
helical monomers by forming an intrachain hydrogen
bond with the N-terminal main chain nitrogen atom.
It should be noted that trimer formation of ccb-p
and its variants was unexpected and surprising be-
cause the peptides were originally designed to fold
into two-stranded parallel coiled-coil structures (see
above). This discrepancy suggests that in short coiled-
coils residues at the e and g positions may play a
more prominent role in specifying and stabilizing the
oligomerization state than in longer structures.
The propensities of ccb-p, ccb-Met, and ccb-
MetO to undergo a conformational switch was as-
sessed by CD at elevated temperatures. Figure 3, a
Fig. 3. ccb forms amyloid-like aggregates rich in b-sheet structure at elevated temperatures. (a), a-to-b transition of ccb-Met (0.2 mg/ml)
monitored in PBS at 37C by CD. The spectra were recorded in 10 min time intervals. (b), Time course of the a-to-b transition of ccb-Met
(0.2 mg/ml in PBS) monitored by CD at 37C and at 205 nm in the absence (d) and presence (s) of 5% (w/w) preformed ﬁbrils. (c), TEM
micrograph of negatively stained ccb-p protoﬁbrillar intermediates obtained in PBS. Scale bar, 50 nm. (d), TEM micrograph of negatively
stained mature ccb-p ﬁbrils obtained in water. Scale bar, 50 nm. (e), Congo red stained ccb-p ﬁbril sample obtained in PBS and imaged under
cross-polarized light. Scale bar, 50 lm.
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and b, shows the structural conversion of the ccb-Met
coiled-coil. At 37C and at a peptide concentration of
0.2 mg/ml the minima of the CD spectrum at 208 and
222 nm transformed within 1 h into a single mini-
mum centered at 217 nm indicating a change in
conformation from an a-helix into a b-sheet–rich
structure (Fig. 3a). After 2 h, the CD signal at
217 nm started to decrease probably as a result of the
formation of high molecular weight aggregates. No
helical signal was regained upon cooling indicating
that the heat-induced self-assembled b-sheet struc-
tures is irreversible. The change in structure was ob-
served after a lag time of 12 min (Fig. 3b). The
length of the lag phase, as well as the slope of the
growth phase, was temperature and concentration
dependent (not shown). Addition of preformed
aggregates rich in b-sheet structure shortened the
transition time by eliminating the lag phase, and also
accelerating the growth rate (Fig. 3b). These ﬁndings
are consistent with a nucleation-dependent self-
assembly process for the peptide (Rochet and Lans-
bury 2000). Unexpectedly, ccb-p aggregation was
found to be 60 times slower than that of the
methionine peptide (not shown; (Kammerer et al.
2004)). In marked contrast to the aggregation
behavior of ccb-p and ccb-Met, no aggregate forma-
tion was observed for the ccb-MetO derivative even
after incubation of a 20 mg/ml peptide solution for
72 h at 90C or after attempts to seed the system by
addition of preformed ccb-Met ﬁbrils. As shown in
Fig. 2b (inset), at a peptide concentration of 0.15 mg/
ml the thermal denaturation proﬁle recorded from
ccb-MetO by CD at 222 nm revealed a fully reversible
sigmoidal transition with a single midpoint of the
unfolding transition, Tm, centered at 46C.
The structure of ccb-p and ccb-Met in their b-
sheet-rich form was analyzed by negative stain TEM.
As shown in Figure 3c, peptide samples that were
withdrawn during the early stages of assembly and
inspected by TEM, revealed a series of discrete pre-
ﬁbrillar structures. These structures resemble the
protoﬁbrillar aggregates reported for a wide range of
disease and non-disease related proteins (Walsh et al.
1999; Rochet and Lansbury 2000; Bucciantini et al.
2002). TEM micrographs of mature peptide samples
revealed twisted and non-branched ﬁbres 7 to 8 nm in
diameter (Fig. 3d). The ﬁbrils are strikingly similar to
amyloid ﬁbril assemblies reported for other peptides
and proteins (Cohen et al. 1982). Furthermore,
addition of Congo red to the sample produced a
characteristic green birefringence under cross-polar-
ized light (Fig. 3e). Importantly, detailed biophysical
analyzes using Fourier-transform infrared spectros-
copy, atomic force microscopy, scanning transmission
electron microscopic mass-per-length measurements,
X-ray ﬁbre diﬀraction, and solid-state nuclear mag-
netic resonance were fully consistent with this con-
clusion. They provided solid support for a detailed
molecular model for the peptide in its amyloid-like
ﬁbrillar state (Kammerer et al. 2004).
CONCLUSIONS
An essential requirement in the investigation of the
relative contribution of factors such as sequence con-
text, complementary side chain interactions, and pro-
tein stability to the formation of amyloid ﬁbrils is the
availabilityofwell deﬁnedmodel systems. In this study,
weusedaminimalisticde novodesign approach (Fig. 1)
based on the coiled-coil structural motif to address
these questions. Our solution and X-ray crystallo-
graphic data are consistentwith the ccb system forming
a stable native-like coiled-coil structure (Fig. 2). Sim-
ilarly, the data obtained on the aggregated state (Fig. 3
and ref. (Kammerer et al. 2004)) are consistent with
well-ordered amyloid-like ﬁbrils in which the peptide
molecules are packed in a speciﬁc manner. These
ﬁndings demonstrate that we have successfully de-
signed a simple peptide sequence system that folds into
a protein-like structure under ambient solution con-
ditions and transforms into ﬁbrils characteristic of
amyloid structures at elevated temperatures.
A signiﬁcant difference to other de novo model
systems that form amyloid aggregates (Cerpa et al.
1996; Zhang and Rich 1997; Janek et al. 1999; West
et al. 1999; Fezoui et al. 2000; Otzen et al. 2000;
Takahashi et al. 2000; Ciani et al. 2002; Lopez De La
et al. 2002; Tjernberg et al. 2002b) is that our
designed ‘miniprotein’ adopts a stable tertiary fold
despite its simplicity. This represents an important
feature because it allows us to study the relationship
between the stability of the native state of a protein
and amyloid formation in a simpliﬁed manner. This is
exempliﬁed by the dramatic structural eﬀects of a
small chemical modiﬁcation introduced by oxidizing
methionine residues at selected hydrophobic posi-
tions. The insertion of only two oxygen atoms com-
pletely abolished amyloid ﬁbril formation of the
peptide while not signiﬁcantly interfering with its
coiled-coil structure. Importantly, these ﬁndings
suggest that speciﬁc hydrophobic packing interac-
tions can play a major role in the kinetics of amyloid
formation (Kammerer et al. 2004).
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This conclusion may help to rationalize a number
of pathological conditions linked to speciﬁc hydro-
phobic mutations that have little effect on the overall
stability of the protein or on the other features
mentioned above (Liemann and Glockshuber 1999;
Chiba et al. 2003; Chiti et al. 2003). The character-
istics of ccb make this model system thus highly
suitable for probing molecular details of the assembly
of amyloid structures (Miranker 2004). Its speciﬁc
design together with the obtained detailed structural
information now allows us to explore systematically
both the eﬀects of side chain packing interactions
within the amyloid ﬁbril and their relationship to the
kinetics of amyloid ﬁbril formation. This approach
has an advantage over studies of natural dis-
ease-related models, where the complexity and size of
the polypeptides often hinders a detailed rational
approach to these processes.
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